白云山(00874)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

00874 白云山

已收盘 07-23 16:08:06

15.900

+0.140

+0.89%

最高15.990	最低15.730	成交量44.66万
今开15.980	昨收15.760	日振幅1.65%
总市值258.53亿	流通市值34.96亿	总股本16.26亿
成交额707.52万	换手率0.20%	流通股本2.20亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"00874","market":"HK","secType":"STK","nameCN":"白云山","latestPrice":15.9,"timestamp":1784794086003,"preClose":15.76,"halted":0,"volume":446600,"delay":0,"changeRate":0.008883248730964504,"floatShares":219900000,"shares":1626000000,"eps":2.123176051313014,"marketStatus":"已收盘","change":0.14,"latestTime":"07-23 16:08:06","open":15.98,"high":15.99,"low":15.73,"amount":7075236,"amplitude":0.016497,"askPrice":15.9,"askSize":6000,"bidPrice":15.83,"bidSize":30000,"shortable":3,"etf":0,"ttmEps":2.09648998458414,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1784856600000},"marketStatusCode":5,"adr":0,"listingDate":878140800000,"exchange":"SEHK","adjPreClose":15.76,"dividendRate":0.060164,"openAndCloseTimeList":[[1784770200000,1784779200000],[1784782800000,1784793600000]],"volumeRatio":0.476245,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"600332","market":"SH","secType":"STK","nameCN":"白云山","latestPrice":21.9,"timestamp":1784790000000,"preClose":22.03,"halted":0,"volume":8619700,"delay":0,"premium":"-37.25"}},"requestUrl":"/m/hq/s/00874","defaultTab":"news","newsList":[{"id":"2653296746","title":"白云山：公司目前暂无股份回购计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2653296746","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653296746?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:09","pubTimestamp":1784801368,"startTime":"0","endTime":"0","summary":"证券之星消息，白云山07月23日在投资者关系平台上答复投资者关心的问题。公司目前暂无股份回购计划，相关信息请以公司公开披露的信息为准；公司通过接待投资者调研、业绩路演、举办网上业绩说明会等多种方式与投资者进行沟通，我们将继续积极传递公司价值。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300037530.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK1197","BK1521","BK0097","BK0012","BK1191","BK1515","BK0096","BK0028","600332","00874","BK0175","BK0239","BK0070","BK1606","BK0183","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653228746","title":"白云山：公司将继续积极传递公司价值，做好市值管理工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2653228746","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653228746?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:09","pubTimestamp":1784801350,"startTime":"0","endTime":"0","summary":"证券之星消息，白云山(600332)07月23日在投资者关系平台上答复投资者关心的问题。投资者提问：股价屡创新低公司有没有什么措施白云山回复：尊敬的投资者您好，股价受股票市场行情等多种因素影响，公司将继续积极传递公司价值，做好市值管理工作，感谢您的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300037520.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600332","BK1515","BK0028","BK1521","BK1606","BK0188","BK1191","BK0096","BK0183","00874","BK0239","BK0012","BK0097","BK0070","BK0196","BK1197","BK0175"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653674621","title":"白云山：已完成大部分品牌授权整顿清理工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2653674621","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2653674621?lang=zh_cn&edition=full","pubTime":"2026-07-23 18:09","pubTimestamp":1784801348,"startTime":"0","endTime":"0","summary":"证券之星消息，白云山(600332)07月23日在投资者关系平台上答复投资者关心的问题。投资者提问：请问董秘，公司清理贴牌的进展如何？其中是否包括健码制药的白云山肺槲皮素紫苏籽槐米玉竹百合石斛复合片，是什么批号？白云山回复：尊敬的投资者您好，感谢您的关注！公司已强化相关制度及加强品牌管理，持续清理整顿存量贴牌授权产品，截止目前已完成大部分品牌授权整顿清理工作。目前该产品是公司属下企业自营产品。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072300037515.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0097","BK1521","BK0070","BK1191","BK1197","BK0028","BK1606","00874","BK0012","BK0175","600332","BK0196","BK0188","BK0096","BK0183","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652294849","title":"7月20日白云山现615.37万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2652294849","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652294849?lang=zh_cn&edition=full","pubTime":"2026-07-20 17:47","pubTimestamp":1784540879,"startTime":"0","endTime":"0","summary":"证券之星消息，7月20日白云山发生大宗交易，交易数据如下：大宗交易成交价格24.4元，相对当日收盘价溢价8.98%，成交25.22万股，成交金额615.37万元，买方营业部为东方证券股份有限公司上海黄浦区中华路证券营业部，卖方营业部为东方证券股份有限公司上海黄浦区中华路证券营业部。近三个月该股共发生1笔大宗交易，合计成交2522.0手，溢价成交1笔。截至2026年7月20日收盘，白云山报收于22.39元，上涨0.95%，换手率1.17%，成交量16.46万手，成交额3.66亿元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072000027627.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1606","BK0028","BK0096","BK1521","BK0183","BK0196","BK0012","BK0188","BK1515","BK0097","BK0239","00874","600332","BK1191","BK1197","BK0175","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651584492","title":"【券商聚焦】光大证券：议优先布局经营稳健、业绩扎实或者股息类中药标的","url":"https://stock-news.laohu8.com/highlight/detail?id=2651584492","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651584492?lang=zh_cn&edition=full","pubTime":"2026-07-16 08:54","pubTimestamp":1784163265,"startTime":"0","endTime":"0","summary":"金吾财讯 | 光大证券研究指，近期，中药板块持续上涨，主要受到市场避险、政策利好、业绩催化和估值底部等多重因素共同推动，中期配置价值显著，后市偏乐观。建议优先布局经营稳健、业绩扎实或者高股息类中药标的。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjJmNDVlM2IxNTc1MzAyMDFjYTFhODQyNzEzMTQ0NzU5OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1985990","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","BK1515","BK0276","00570","601788","03613","BK0012","BK1570","BK1606","VIG","BK0028","BK1191","BK1521","00874","06178","BK1219","BK0188","03320","BK4588","BK1147","BK1197","BK1564","BK0183","BK4585","02273","02877","01643","02161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650154816","title":"每周股票复盘：白云山（600332）子公司药品通过一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2650154816","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650154816?lang=zh_cn&edition=full","pubTime":"2026-07-12 01:58","pubTimestamp":1783792691,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，白云山报收于21.29元，较上周的21.19元上涨0.47%。公司控股子公司广州白云山天心制药股份有限公司收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，地塞米松磷酸钠注射液已通过仿制药质量和疗效一致性评价。通过一致性评价有助于提升产品市场竞争力，但后续销售受政策与市场因素影响存在不确定性。公司控股子公司广州医药股份有限公司拟在广州产权交易所预挂牌，通过增资扩股方式引入战略投资者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071200000528.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0096","BK0196","BK0070","BK0012","BK0097","BK0028","BK1515","BK1191","BK1521","BK0183","600332","BK0175","BK0239","BK0188","00874","BK1606","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650713511","title":"白云山（600332）披露子公司增资扩股事项预挂牌公告，7月10日股价上涨0.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650713511","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650713511?lang=zh_cn&edition=full","pubTime":"2026-07-10 22:18","pubTimestamp":1783693107,"startTime":"0","endTime":"0","summary":"截至2026年7月10日收盘，白云山报收于21.29元，较前一交易日上涨0.33%，最新总市值为346.13亿元。该股当日开盘21.12元，最高21.47元，最低20.91元，成交额达1.89亿元，换手率为0.63%。近日，广州白云山医药集团股份有限公司发布《关于子公司增资扩股事项预挂牌的提示性公告》。公告显示，公司控股子公司广州医药股份有限公司拟在广州产权交易所预挂牌，通过增资扩股方式引入战略投资者。本次增资扩股发行股票不超过920,000,000股，预计募集资金总额10亿元至30亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071000044422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0183","600332","BK1197","BK0012","BK0028","BK0188","BK0175","BK1515","BK1606","BK0196","BK1191","BK0096","BK0070","00874","BK0097","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1151683641","title":"白云山（00874）多款药品新入2026年版国家基药目录 对业绩短期影响有限","url":"https://stock-news.laohu8.com/highlight/detail?id=1151683641","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1151683641?lang=zh_cn&edition=full","pubTime":"2026-07-10 20:06","pubTimestamp":1783685162,"startTime":"0","endTime":"0","summary":"2026年7月10日，广州白云山医药集团股份有限公司公告称，国家卫生健康委员会等部门近日发布的《国家基本药物目录》中，公司旗下多家生产企业共有14个剂型/规格产品新进入目录，6个剂型/规格产品退出目录。公司表示，本次产品进入《国家基本药物目录》有利于市场拓展及销售规模提升，短期预计不会对经营业绩产生重大影响；退出目录的产品因销售占比较低，对经营业绩亦无重大影响。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00874"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650803321","title":"白云山：2026年第一季度，公司实现营业收入约232.78亿元，同比增长3.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2650803321","media":"证券日报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650803321?lang=zh_cn&edition=full","pubTime":"2026-07-10 19:35","pubTimestamp":1783683300,"startTime":"0","endTime":"0","summary":"证券日报网7月10日讯 ，白云山在接受调研者提问时表示，2026年第一季度，公司实现营业收入约232.78亿元，同比增长3.58%；归属于本公司股东的净利润为17.84亿元，同比下降2.06%；扣非后归属于本公司股东的净利润约17.03亿元，同比增长1.72%。\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/hk/2026-07-10/doc-inihinfx8450737.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-07-10/doc-inihinfx8450737.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["600332","00874"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650184133","title":"白云山：附属公司广州医药拟增资扩股募集10亿至30亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2650184133","media":"南方财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650184133?lang=zh_cn&edition=full","pubTime":"2026-07-10 18:38","pubTimestamp":1783679893,"startTime":"0","endTime":"0","summary":"南财智讯7月10日电，白云山（00874.HK）发布自愿公告，披露其附属公司广州医药股份有限公司拟通过增资扩股方式引入战略投资者，并于广州产权交易所进行信息预披露。本次增资扩股拟发行股票不超过9.20亿股，预计募集资金总额在人民币10.00亿元至30.00亿元之间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607103801991293.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1606","BK1197","BK1515","159938","BK0028","BK0175","BK1161","BK0096","BK0097","600332","BK0196","BK0188","BK0070","00874","BK0012","09939","BK0239","BK1521","BK1191","BK0183","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109910010","title":"白云山(00874)披露：子公司广州医药拟增资扩股，计划募资10至30亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=1109910010","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109910010?lang=zh_cn&edition=full","pubTime":"2026-07-10 18:35","pubTimestamp":1783679742,"startTime":"0","endTime":"0","summary":"2026年7月10日，广州白云山医药集团股份有限公司公告称，其持股90.92%的非全资附属公司广州医药股份有限公司拟通过增资扩股方式引入战略投资者，并已计划在广州产权交易所进行信息预披露。白云山表示，增资扩股完成后，公司对广州医药的实际控制权及控股地位将保持不变。财务数据显示，截至2025年12月31日，广州医药资产总额为375.79亿元，负债总额295.86亿元，所有者权益79.93亿元；2025年度实现营业收入581.69亿元，归属母公司净利润6.09亿元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00874"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650184377","title":"白云山(00874.HK)附属广州医药拟通过增资扩股的方式引入战略投资者 预计募资10亿-30亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2650184377","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650184377?lang=zh_cn&edition=full","pubTime":"2026-07-10 18:33","pubTimestamp":1783679590,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1606","BK1515","BK1521","BK1191","BK1197","00874","BK1161","BK1574","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198290604","title":"白云山(00874)子公司地塞米松磷酸钠注射液获一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=1198290604","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198290604?lang=zh_cn&edition=full","pubTime":"2026-07-09 18:56","pubTimestamp":1783594573,"startTime":"0","endTime":"0","summary":"2026年7月9日，广州白云山医药集团股份有限公司公告称，其控股子公司广州白云山天心制药股份有限公司收到国家药品监督管理局签发的《药品补充申请批准通知书》，地塞米松磷酸钠注射液通过仿制药质量和疗效一致性评价，通知书编号为2026B04338，受理号为CYHB2450616。白云山方面表示，产品通过一致性评价有望提升市场竞争力，但药品生产和销售仍受国家政策及市场环境等因素影响，存在不确定性。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00874"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122236533","title":"白云山（00874）董事会通过聘任两名副总经理等四项议案","url":"https://stock-news.laohu8.com/highlight/detail?id=1122236533","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1122236533?lang=zh_cn&edition=full","pubTime":"2026-07-09 18:51","pubTimestamp":1783594276,"startTime":"0","endTime":"0","summary":"广州白云山医药集团股份有限公司7月9日公告称，公司第十届董事会第三次会议已于2026年7月9日以通讯表决方式召开。会议应出席董事11人，实际出席11人，会议召集、召开程序符合《公司法》及《公司章程》相关规定。董事会审议并以11票同意、0票反对、0票弃权的结果通过以下四项议案：","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00874"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125343842","title":"白云山（00874）公布董事会战略发展与投资委员会实施细则 规范重大投资决策权限","url":"https://stock-news.laohu8.com/highlight/detail?id=1125343842","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1125343842?lang=zh_cn&edition=full","pubTime":"2026-07-09 18:51","pubTimestamp":1783594262,"startTime":"0","endTime":"0","summary":"广州白云山医药集团股份有限公司7月9日公告称，公司第十届董事会第三次会议当日审议通过《董事会战略发展与投资委员会实施细则》，自通过之日起生效，适用于公司及其直接或间接投资的全资、控股、实际控制企业及其分支机构。委员会下设工作小组，负责决策前期准备及执行相关决议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00874"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173931162","title":"白云山（00874）发布《外部信息使用人管理制度》 强化内幕信息合规管理","url":"https://stock-news.laohu8.com/highlight/detail?id=1173931162","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173931162?lang=zh_cn&edition=full","pubTime":"2026-07-09 18:50","pubTimestamp":1783594256,"startTime":"0","endTime":"0","summary":"2026年7月9日，广州白云山医药集团股份有限公司在香港联交所披露海外监管公告，全文转发其于上海证券交易所网站刊载的《外部信息使用人管理制度》。该制度已获公司第十届董事会第三次会议审议通过，并自董事会通过之日起实施。截至本公告披露日，公司董事会由11名董事组成，包括6名执行董事、1名非执行董事及4名独立非执行董事。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00874"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650251189","title":"白云山最新公告：子公司地塞米松磷酸钠注射液通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2650251189","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650251189?lang=zh_cn&edition=full","pubTime":"2026-07-09 18:41","pubTimestamp":1783593682,"startTime":"0","endTime":"0","summary":"白云山(600332.SH)公告称，公司控股子公司天心制药的地塞米松磷酸钠注射液(1ml:5mg)通过仿制药质量和疗效一致性评价，该药品主要用于过敏性与自身免疫性炎症性疾病。2025年该药品在国内销售额为2.36亿元，天心制药销售收入为283.65万元。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900035270.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK1515","BK0012","BK0175","BK1191","BK1521","00874","BK0239","BK0097","BK0070","BK0183","BK1197","600332","BK1606","BK0196","BK0028","BK0096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648946686","title":"白云山（600332）披露截至2026年6月30日证券变动月报表，7月2日股价上涨1.76%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648946686","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648946686?lang=zh_cn&edition=full","pubTime":"2026-07-02 22:50","pubTimestamp":1783003827,"startTime":"0","endTime":"0","summary":"截至2026年7月2日收盘，白云山报收于20.79元，较前一交易日上涨1.76%，最新总市值为338亿元。该股当日开盘20.43元，最高20.88元，最低20.33元，成交额达1.99亿元，换手率为0.69%。近日，广州白云山医药集团股份有限公司披露截至2026年6月30日的证券变动月报表。公告显示，公司H股和A股的法定/注册股本、已发行股份及库存股份数目均无变动。A股于上交所上市，证券代码600332，上月底结存及本月底结存均为1,405,890,949股，面值人民币1元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200042493.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1606","BK0028","BK0096","BK1521","BK0183","BK0196","BK0012","BK0188","BK1515","BK0097","BK0239","00874","600332","BK1191","161027","BK1197","BK0175","BK0070"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128962097","title":"白云山更新6月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1128962097","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128962097?lang=zh_cn&edition=full","pubTime":"2026-07-02 16:45","pubTimestamp":1782981944,"startTime":"0","endTime":"0","summary":"广州白云山医药集团股份有限公司（股票代码：00874）于2026年7月2日发布2026年6月股份变动月报表。公告显示，截至2026年6月30日，公司已发行股份及注册股本未发生新增发行、购回、注销或库藏股变动。\n根据报告披露，白云山的已发行H股股份数量为219,900,000股，A股股份数量为1,405,890,949股，两类股份合计本月底仍维持在1,625,790,949股，与上月底数值一致。公司表示，本期无新增股份期权、股权激励或可转债，亦无回购或注销安排。\n公司同时确认，已遵守香港联交所《上市规则》及相关法律法规的要求。本次公告由公司秘书黄雪贞签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00874"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646139593","title":"每周股票复盘：白云山（600332）终止人才公寓项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2646139593","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646139593?lang=zh_cn&edition=full","pubTime":"2026-06-28 02:15","pubTimestamp":1782584113,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，白云山报收于19.77元，较上周的20.78元下跌4.86%。本周，白云山6月23日盘中最高价报21.29元。本周关注点来自公司公告汇总：白云山终止广药白云山保障性租赁住房暨人才公寓建设项目。会议决定终止广药白云山保障性租赁住房暨人才公寓建设项目，原因为房地产市场环境变化及政策调整导致项目运营存在不确定性，终止项目预计不会对公司财务和经营状况产生重大不利影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800000521.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1197","BK0028","BK0096","BK0196","BK1191","BK0183","BK1521","00874","BK0097","BK1515","BK0188","BK0175","BK0070","BK0012","600332","BK1606"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.gybys.com.cn","stockEarnings":[{"period":"1week","weight":0.0006},{"period":"1month","weight":0.067},{"period":"3month","weight":-0.0282},{"period":"6month","weight":-0.1326},{"period":"1year","weight":-0.0921},{"period":"ytd","weight":-0.0798}],"compareEarnings":[{"period":"1week","weight":0.0086},{"period":"1month","weight":0.0473},{"period":"3month","weight":-0.0395},{"period":"6month","weight":-0.0694},{"period":"1year","weight":-0.0094},{"period":"ytd","weight":-0.0288}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"广州白云山医药集团股份有限公司是一家主要从事医药健康业务的中国公司。该公司通过四个分部运营。大南药分部从事中西成药、化学原料药、生物医药和天然药物等的研发、制造与销售。大健康分部从事饮料、食品、保健品等产品的生产、研发与销售。大商业分部从事医药产品、医疗器械、保健品等的批发、零售与进出口业务。大医疗分部从事医疗服务、中医养生、现代养老以及医疗器械产业的投资。该公司主要在中国国内和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.009956},{"month":2,"riseRate":0.714286,"avgChangeRate":0.058376},{"month":3,"riseRate":0.586207,"avgChangeRate":0.049652},{"month":4,"riseRate":0.62069,"avgChangeRate":0.081835},{"month":5,"riseRate":0.551724,"avgChangeRate":0.044342},{"month":6,"riseRate":0.482759,"avgChangeRate":0.019085},{"month":7,"riseRate":0.448276,"avgChangeRate":-0.011865},{"month":8,"riseRate":0.392857,"avgChangeRate":-0.036816},{"month":9,"riseRate":0.428571,"avgChangeRate":-0.010726},{"month":10,"riseRate":0.428571,"avgChangeRate":0.004047},{"month":11,"riseRate":0.448276,"avgChangeRate":0.008322},{"month":12,"riseRate":0.535714,"avgChangeRate":0.023783}],"exchange":"SEHK","name":"白云山","nameEN":"BAIYUNSHAN PH"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"白云山(00874)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供白云山(00874)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"白云山,00874,白云山股票,白云山股票老虎,白云山股票老虎国际,白云山行情,白云山股票行情,白云山股价,白云山股市,白云山股票价格,白云山股票交易,白云山股票购买,白云山股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"白云山(00874)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供白云山(00874)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}